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   ABSTRACT 
  Objective      This study assessed the efﬁ  cacy and safety of 
canakinumab, a fully human anti-interleukin 1β monoclonal 
antibody, for prophylaxis against acute gouty arthritis ﬂ  ares 
in patients initiating urate-lowering treatment.   
  Methods      In this double-blind, double-dummy, dose-
ranging study, 432 patients with gouty arthritis initiating 
allopurinol treatment were randomised 1:1:1:1:1:1:2 
to receive: a single dose of canakinumab, 25, 50, 100, 
200, or 300 mg subcutaneously; 4×4-weekly doses of 
canakinumab (50+50+25+25 mg subcutaneously); 
or daily colchicine 0.5 mg orally for 16 weeks. Patients 
recorded details of ﬂ  ares in diaries. The study aimed 
to determine the canakinumab dose having equivalent 
efﬁ  cacy to colchicine 0.5 mg at 16 weeks.   
  Results      A dose-response for canakinumab was not 
apparent with any of the four predeﬁ  ned dose-response 
models. The estimated canakinumab dose with 
equivalent efﬁ  cacy to colchicine was below the range 
of doses tested. At 16 weeks, there was a 62% to 72% 
reduction in the mean number of ﬂ  ares per patient for 
canakinumab doses ≥50 mg versus colchicine based 
on a negative binomial model (rate ratio: 0.28–0.38, 
p≤0.0083), and the percentage of patients experiencing 
≥1 ﬂ  are was signiﬁ  cantly lower for all canakinumab 
doses (15% to 27%) versus colchicine (44%, p<0.05). 
There was a 64% to 72% reduction in the risk of 
experiencing ≥1 ﬂ  are for canakinumab doses ≥50 
mg versus colchicine at 16 weeks (hazard ratio (HR): 
0.28–0.36, p≤0.05). The incidence of adverse events 
was similar across treatment groups.   
  Conclusions    Single  canakinumab  doses  ≥50 mg or four 
4-weekly doses provided superior prophylaxis against 
ﬂ  ares compared with daily colchicine 0.5 mg.           
  INTRODUCTION 
  Gouty arthritis is a painful inﬂ  ammatory  arthri-
tis that becomes increasingly prevalent with age, 
affecting around 10% of men and 6% of women 
over 70 years old.    1        2    It results from deposition of 
monosodium urate (MSU) crystals in joints, which 
leads to painful inﬂ  ammatory acute gouty arthri-
tis ﬂ  ares.    3        4    An increasing number of patients have 
comorbidities which make standard therapies inap-
propriate.    5    Such patients may develop difﬁ  cult-to-
treat disease, characterised by frequent ﬂ  ares and 
persistent inﬂ  ammation between ﬂ  ares which con-
tribute to joint damage    6    and have a major impact 
on health-related quality of life    7        8    and an individu-
al’s ability to work.    9    
  Long-standing elevated body uric acid pools 
can lead to increased serum urate (SU) levels and 
formation of MSU crystals. An important goal in 
the long-term management of gouty arthritis is the 
reduction of SU levels to below 6 mg/dl so as to 
prevent formation of new crystals, dissolve exist-
ing crystals and ultimately decrease the incidence 
of ﬂ  ares.    10        11    This is achieved with urate lowering 
therapies (ULT).    12    Allopurinol is the most com-
monly used ULT and the current standard of care. 
  During the ﬁ  rst weeks and months after initiating 
ULT, rapid reductions in SU levels can induce acute 
gouty arthritis ﬂ  ares.    13       –       17    Therefore, when initiat-
ing a patient on ULT, prophylactic low-dose anti-
inﬂ  ammatory treatment is recommended to prevent 
ﬂ  ares and foster compliance with ULT. Low-dose 
colchicine is the most commonly prescribed drug 
for prophylaxis in patients initiating ULT, but it has 
signiﬁ  cant shortcomings. Some patients have con-
traindications to colchicine whereas others do not 
tolerate colchicine or still experience ﬂ  ares. Evidence 
for the efﬁ  cacy of colchicine as prophylaxis against 
ﬂ  ares comes from two small studies and a larger 
study performed 50 years ago.    18       –       20    Three recent 
trials used colchicine for prophylaxis in patients 
initiating ULT (with febuxostat), but provide lim-
ited data on the efﬁ  cacy of colchicine.    17        21        22    There 
is therefore a need for more rigorous assessment 
of the efﬁ  cacy of colchicine as prophylaxis against 
ﬂ  ares following ULT initiation and the introduction 
of alternative therapies. 
  Several lines of evidence suggest that the proin-
ﬂ  ammatory cytokine, interleukin 1β (IL-1β), plays 
a key role in mediating the initiation of inﬂ  amma-
tion in gouty arthritis in a similar manner to that 
occurring in the hereditary autoinﬂ  ammatory syn-
drome, cryopyrin-associated periodic syndrome 
(CAPS),    23        24    and may also contribute to joint 
destruction in gouty arthritis.    6        25        26    This suggests 
that selective blockade of IL-1β signalling may pro-
vide effective prophylaxis against ﬂ  ares in patients 
with gouty arthritis and is supported by results 
showing that IL-1β blockade with canakinumab, 
a fully human monoclonal antibody to IL-1β with 
a half-life of 3–4 weeks,    27    can effectively reduce 
pain, inﬂ  ammation and the risk of recurrent ﬂ  ares 
in patients with acute gouty arthritis.    28    Here, we 
report the results of a dose-ranging, active-con-
trolled phase II trial to assess the efﬁ  cacy, safety and 
tolerability of canakinumab as prophylaxis against 
ﬂ  ares in patients initiating allopurinol treatment.   
  Additional data are    ▶
published online only. To view 
these ﬁ  les please visit the 
journal online at (http://ard.bmj.
com).   
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number of ﬂ  ares per patient, proportion of patients with at least 
one ﬂ  are, time to ﬁ  rst ﬂ  are, average duration of ﬂ  ares and CRP 
levels (see supplementary material for further details). Safety 
variables included the incidence of AEs, serious AEs (SAEs) and 
infectious AEs, the incidence and severity of injection-site reac-
tions, and immunogenicity.   
    Sample size determination and statistical analysis 
  A sample size of 350 patients (50 patients in each of the 
5   canakinumab single-dose groups and 100 patients in the colchi-
cine group) was considered sufﬁ  cient to give a 95% conﬁ  dence 
interval (CI) of the target dose with reasonable precision. In 
order to increase the precision of the analysis the planned total 
sample size of 400 was increased to approximately 440 patients 
(see supplementary material for more details). 
  A preplanned interim analysis was performed when 200 
patients had completed 16 weeks. Efﬁ  cacy and safety analyses 
were then performed when all patients had completed the study 
(24 weeks). 
  For determination of the primary outcome, the number of 
ﬂ  ares per patient during 16 weeks was modelled using a nega-
tive binomial distribution and a common overdispersion (vari-
ance divided by expectation minus 1) for all treatment arms (see 
supplementary material for more details). 
  The main secondary outcome was the mean number of 
ﬂ  ares per patient at 16 weeks. Data were analysed according 
to an analysis of covariance (ANCOVA) with treatment group, 
allopurinol dose at baseline and BMI at baseline as covariates. 
However, as the distribution of ﬂ  ares per patient was observed 
to be skewed, the preplanned ANCOVA was considered inap-
propriate for these data. Therefore a post hoc analysis using a 
negative binomial model with treatment group, allopurinol dose 
at baseline and BMI at baseline as covariates and log (time on 
study) as an offset was performed with an adjustment made for 
multiplicity (see supplementary material for further details of 
analyses for secondary outcomes).     
  RESULTS 
    Baseline demographics and disease characteristics 
  Between December 2008 and August 2009, 432 patients from 
75 centres in 16 countries were randomised to treatment; 391 
patients (90.5%) completed the study (  ﬁ  gure 1  ). Demographic 
and baseline disease characteristics were generally well bal-
anced across treatment groups (  table 1  ). Most patients were men 
(89% to 100%) and 28% to 44% had had gouty arthritis for 
at least 10 years. At baseline, many patients had very high SU 
levels (≥9 mg/dl; 35% to 55%). The mean number of ﬂ  ares in 
the past year ranged from 3.6 to 4.7 for the different treatment 
groups. Approximately 6% of patients had reduced renal func-
tion, deﬁ  ned as having an estimated creatinine clearance rate 
(CrCl) below the normal range for age and sex (  table 1  ).       
    Primary outcome: determination of canakinumab target dose 
  No evidence of a dose-response was seen in any of the four 
predeﬁ  ned dose response models. The estimated canakinumab 
dose with equivalent efﬁ  cacy to colchicine was below the range 
of canakinumab doses tested.   
  Secondary  outcomes 
  Clinical  outcomes 
  The least-squares (LS) mean number of ﬂ  ares per patient for the 
16 weeks (according to the preplanned ANCOVA) was lower for 
  METHODS 
  Study  design 
  This was a 24-week, dose-ranging, multicentre, double-blind, 
double-dummy, active-controlled study and was approved by 
all responsible independent ethics committees. The study was 
performed in accordance with the International Conference on 
Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH) Harmonised Tripartite 
Guidelines for Good Clinical Practice and the ethical principles 
laid down in the Declaration of Helsinki, and all patients provided 
written informed consent. The trial was registered with   http://
www.clinicaltrials.gov   (registration number: NCT00819585). 
  At screening, patients indicated which of their joints was most 
affected by previous gouty arthritis ﬂ  ares. Eligible patients were 
subsequently randomised 1:1:1:1:1:1:2 to receive a single dose of 
canakinumab, 25 mg, 50 mg, 100 mg, 200 mg, or 300 mg on day 
1, or four canakinumab doses administered at 4-weekly inter-
vals (50 mg on day 1 and at week 4, and 25 mg at weeks 8 and 
12), or daily oral doses of colchicine 0.5 mg given for 16 weeks. 
In order to achieve blinding for patients and investigators, all 
patients received subcutaneous injections of canakinumab or 
canakinumab placebo on day 1, and at weeks 4, 8 and 12, and 
took capsules of colchicine or colchicine placebo daily for 16 
weeks (see supplementary material for details). Patients were 
followed for 24 weeks. 
  Allopurinol treatment (100–300 mg) was initiated at baseline 
or within 1 month before baseline and was administered to all 
randomised patients once daily for 24 weeks (see supplementary 
material for details). Patients could receive rescue medication as 
needed (see supplementary material for details).   
  Patients 
  Inclusion criteria were: age 18–80 years, diagnosis of gouty 
arthritis as deﬁ  ned by the American College of Rheumatology 
1977 preliminary criteria,    29    having had at least two gouty arthri-
tis ﬂ  ares in the previous year, body mass index (BMI) of ≤40 kg/
m  2   and willingness to initiate allopurinol treatment or having 
initiated allopurinol treatment within 1 month of screening. 
  Key exclusion criteria were: having a gouty arthritis ﬂ  are 
within 2 weeks of screening, present at screening, or having pain 
associated with a ﬂ  are at screening; history of allergy, contrain-
dication, or intolerance to allopurinol or colchicine (see supple-
mentary material for further details).   
  Assessments 
  Flares were patient reported. For each ﬂ  are, patients recorded in 
a diary the start date, the most affected joint on that day and the 
severity of pain (see supplementary material for further details). 
Patients also recorded rescue medication use and pain for at least 
7 days after the onset of the ﬂ  are or longer if the ﬂ  ares persisted 
for more than 7 days. 
  Safety assessments were performed at scheduled visits (2, 4, 
8, 12, 16, 20 and 24 weeks) and included collection of blood 
samples for assessment of the inﬂ  ammatory marker, C reactive 
protein (CRP), haematology and immunogenicity (at baseline 
and weeks 8, 16 and 24) and doctor’s assessments of local toler-
ability at sites of subcutaneous injections. Adverse events (AEs) 
were reported throughout the study. 
  The primary outcome was determination of the canaki-
numab dose producing equivalent efﬁ  cacy to that achieved with 
colchicine 0.5 mg, with respect to the mean number of ﬂ  ares 
per patient occurring within 16 weeks post randomisation (ie, 
the target dose). Secondary efﬁ  cacy outcomes included: mean 
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signiﬁ  cantly less likely to experience at least one ﬂ  are compared 
with patients treated with colchicine (estimated odds ratio (OR) 
vs colchicine: 0.22–0.47, p≤0.05) (  table 2  ). In addition, time to 
ﬁ  rst new gouty arthritis ﬂ  are was longer with all canakinumab 
groups compared with colchicine 0.5 mg (  ﬁ  gure 2  ) and there 
was a 64% to 72% reduction in the risk of experiencing at least 
one ﬂ  are for canakinumab doses ≥50 mg versus colchicine at 
16 weeks (HR: 0.28–0.36, p≤0.05) (  table 2  ). The average dura-
tion (LS mean) for all ﬂ  ares over the 16-week period was shorter 
in all canakinumab groups compared with colchicine 0.5 mg: 
2.8–4.6 days versus 5.1 days (  table 2  ). Differences in average 
  duration between all canakinumab groups versus colchicine 
0.5 mg, however, were not statistically signiﬁ  cant.     
  CRP  levels 
  An initial decrease in median CRP levels was seen in all treatment 
groups (  ﬁ  gure 3  ). For all canakinumab doses ≥50 mg, median 
CRP values remained consistently lower than in the colchicine 
all canakinumab doses compared with colchicine 0.5 mg; differ-
ences were statistically signiﬁ  cant for the canakinumab 100 mg 
and 300 mg doses (p≤0.05,   table 2  ). (The LS mean number of 
ﬂ  ares per patient is the best-ﬁ  tting unbiased estimate calculated 
from the ANCOVA model.) However, as the distribution of ﬂ  ares 
per patient was observed to be skewed (most patients had no or 
few ﬂ  ares and few had many ﬂ  ares), the preplanned ANCOVA 
was considered inappropriate for these data. Therefore a post 
hoc analysis using a negative binomial model (the model used 
for the primary outcome) was performed after unblinding at 
16 weeks. According to this analysis, there was a 62% to 72% 
reduction in the mean number of ﬂ  ares per patient for canaki-
numab doses ≥50 mg versus colchicine (rate ratio: 0.28–0.38, 
p≤0.0083) (  table 2  ).   
  The percentage of patients experiencing at least one ﬂ  are in 
the 16-week period was lower for all canakinumab groups ver-
sus colchicine 0.5 mg (canakinumab, 15% to 27%; colchicine, 
44%, p≤0.05), and all patients receiving canakinumab were 
 Figure  1        Patient disposition. Patients were recruited from the following countries (number of centres): Argentina (1), Belgium (2), Columbia (5), 
Czech Republic (5), Germany (5), Guatemala (5), Hungary (4), Poland (2), Portugal (3), Russia (7), Singapore (1), Slovakia (6), South Africa (4), Spain 
(4), Taiwan (4), Turkey (8), UK (2) and USA (20).       
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achieved SU levels <6 mg/dl and similar results were reported 
for week 24 (canakinumab, 37.0% to 50.9%; colchicine, 
41.7%).   
  Safety  and  tolerability 
  Safety results for the individual dose groups are summarised 
in   table 3  . The incidence of AEs over the 24-week period was 
group throughout the study and were below the upper limit of 
the normal range (ULN, 3.0 mg/dl) up to week 24.     
  SU  levels 
  At baseline, 85.2% to 92.6% of patients had SU levels ≥6 mg/dl 
(  table 1  ). At 16 weeks 38.9% to 53.7% of patients treated with 
canakinumab and 46.3% of patients treated with colchicine 
  Table  1         Demographic and baseline characteristics (safety set)   
 Variable 
 Canakinumab 
25 mg n=55 
 Canakinumab 
50 mg n=54 
 Canakinumab 
100 mg n=54 
 Canakinumab 
200 mg n=54 
 Canakinumab 
300 mg n=53 
 Canakinumab 
every 4 weeks 
n=53 
 Colchicine 
0.5 mg n=108 
Male, n (%)   55 (100.0)   51 (94.4)   48 (88.9)   50 (92.6)   51 (96.2)   49 (92.5) 101 (93.5)
Age, years
  Mean (SD)   50.7 (9.72)   54.4 (12.18)   51.3 (12.41)   52.6 (10.78)   52.4 (11.30)   52.8 (10.38)   52.4 (10.69)
  Median (range)   52.0 (27–78)   53.0 (32–78)   51.0 (27–79)   53.5 (29–74)   51.0 (30–74)   53.0 (23–72)   54.0 (20–77)
Race, n (%)
  Caucasian  42  (76.4)  43  (79.6)  36  (66.7)  39  (72.2)  36  (67.9)  41  (77.4)  87  (80.6)
  Black   1  (1.8)   1  (1.9)   2  (3.7)   2  (3.7)   3  (5.7)   3  (5.7)   4  (3.7)
  Asian   4  (7.3)   4  (7.4)  10  (18.5)   5  (9.3)   4  (7.5)   2  (3.8)   5  (4.6)
  Other   8  (14.5)   6  (11.1)   6  (11.1)   8  (14.8)  10  (18.9)   7  (13.2)  12  (11.1)
BMI, kg/m  2 
  Mean (SD)   31.03 (4.63)   30.51 (4.35)   29.88 (4.69)   30.60 (4.12)   30.63 (4.64)   29.62 (4.32)   30.30 (4.66)
  Median (range)   30.0 (22–40)   29.9 (22–40)   29.8 (21–40)   30.4 (20–38)   30.4 (17–40)   29.7 (18–38)   29.2 (22–40)
Classiﬁ  cation of gouty arthritis, n (%)*
    Acute monoarticular gouty 
arthritis
 15  (27.3)  19  (35.2)  20  (37.0)  11  (20.4)  17  (32.1)  20  (37.7)  37  (34.3)
    Acute oligoarticular gouty 
arthritis
 27  (49.1)  10  (18.5)  22  (40.7)  20  (37.0)  14  (26.4)  13  (24.5)  28  (25.9)
    Acute polyarticular gouty 
arthritis
 13  (23.6)  25  (46.3)  12  (22.2)  23  (42.6)  22  (41.5)  20  (37.7)  43  (39.8)
Duration of gouty arthritis, n (%)
  <1  year   3  (5.5)   3  (5.6)   2  (3.7)   6  (11.1)   4  (7.5)   2  (3.8)   9  (8.3)
  1–5 years   13 (23.6)   23 (42.6)   25 (46.3)   14 (25.9)   20 (37.7)   15 (28.3)   39 (36.1)
  6–10  years  15  (27.3)   6  (11.1)  12  (22.2)  15  (27.8)  10  (18.9)  18  (34.0)  27  (25.0)
  >10 years   24 (43.6)   22 (40.7)   15 (27.8)   19 (35.2)   19 (35.8)   18 (34.0)   33 (30.6)
Number of ﬂ  ares in previous year
  Mean  (SD)   3.7  (2.27)   4.3  (2.82)   3.6  (2.26)   4.7  (4.51)   4.5  (3.68)   4.4  (4.13)   4.3  (3.82)
  Median  (range)   3.0  (1–14)   3.0  (2–14)   3.0  (2–12)   3.0  (1–25)   4.0  (2–20)   3.0  (2–24)   3.0  (1–25)
Allopurinol dose at baseline, mg daily
  Mean (SD) 261.8 (65.2) 263.0 (65.3) 263.0 (65.3) 257.4 (66.2) 264.2 (65.3) 258.5 (66.3) 261.1 (65.3)
  Median (range) 300.0 (100–300) 300.0 (100–300) 300.0 (100–300) 300.0 (100–300) 300.0 (100–300) 300.0 (100–300) 300.0 (100–300)
    Patients starting allopurinol 
before baseline, n (%)
  6  (10.9)   8  (14.8)  10  (18.5)   8  (14.8)   6  (11.3)   8  (15.1)  12  (11.1)
Creatinine clearance (ml/min),† n (%)
  Low   2  (3.6)   2  (3.7)   2  (3.7)   4  (7.4)   7  (13.2)   2  (3.8)   6  (5.6)
  Normal  31  (56.4)  27  (50.0)  27  (50.0)  26  (48.1)  19  (35.8)  27  (50.9)  58  (53.7)
  High  22  (40.0)  25  (46.3)  25  (46.3)  24  (44.4)  27  (50.9)  24  (45.3)  44  (40.7)
Serum urate, n (%)
  ≥6 mg/dl   50 (90.9)   48 (88.9)   49 (90.7)   50 (92.6)   49 (92.5)   46 (85.2)   96 (88.9)
  ≥9 mg/dl   30 (54.5)   19 (35.2)   20 (37.0)   28 (51.9)   25 (47.2)   22 (41.5)   51 (47.2)
CRP, mg/l
  Mean  (SD)   5.9  (9.88)   9.1  (18.84)   4.5  (8.02)   8.7  (15.40)   7.8  (15.98)   5.9  (6.59)   5.9  (8.30)
  Median  (range)   2.9  (0–70)   3.4  (0–93)   1.8  (0–51)   3.7  (0–93)   3.2  (0–81)   3.1  (0–30)   2.7  (0–49)
SAA, mg/l
  Mean  (SD)   8.7  (11.90)‡  18.8  (53.89)   8.2  (17.35)‡  18.3  (61.46)§  15.6  (61.90)‡  12.4  (22.47)‡  11.5  (28.71)¶
  Median  (range)   3.8  (1–61)   4.9  (0–364)   3.7  (0–120)   5.5  (1–438)   4.3  (1–446)   4.8  (0–139)   4.6  (0–270)
HAQ SDI score
  Mean  (SD)   0.38  (0.47)‡   0.48  (0.60)   0.39  (0.59)   0.38  (0.55)   0.35  (0.58)‡   0.42  (0.63)   0.42  (0.66)
  Median  (range)   0.25  (0–2.0)   0.25  (0–2.1)   0.06  (0–2.6)   0  (0–2.5)   0  (0–2.1)   0.13  (0–2.1)   0.06  (0–2.8)
Employment status
    Working in paid, unpaid or 
voluntary employment
 40  (72.7)  28  (51.9)  35  (64.8)  37  (68.5)  37  (69.8)  35  (66.0)  73  (67.6)
   *p=0.016  from  χ  2   test for comparability across all groups. 
  †Creatinine clearance estimated using the Cockcroft–Gault formula. Normal range for women aged: 16–50 years, 65–110 ml/min; 51–70 years, 50–90 ml/min; 71–110 years, 35–60 
ml/min. Normal range for men aged: 16–50 years, 80–125 ml/min; 51–70 years, 55–100 ml/min; 71–110 years, 40–75 ml/min. 
  ‡Data missing for one patient. 
  §Data missing for two patients. 
  ¶Data missing for four patients. 
  BMI, body mass index; CRP, C reactive protein; HAQ SDI, Health Assessment Questionnaire Standard Disability Index; SAA, serum amyloid A; SD, standard deviation.     
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group, a possible myocardial infarction, but was not regarded 
by the investigator as being related to study medication. Five 
further patients discontinued due to SAEs (canakinumab, n=4 
(1.2%); colchicine, n=1 (0.9%)). Infectious AEs were reported 
in 58 (18.0%) patients receiving canakinumab and 13 (12.0%) 
patients receiving colchicine 0.5 mg (  table 3  ). There was no clear 
pattern with respect to the incidence of infections with either 
treatment. The only infections occurring in more than 1% of 
patients receiving canakinumab were upper respiratory tract 
similar across the six canakinumab groups (51.9% to 58.5%) 
and for the colchicine group (53.7%) (  table 3  ). Most AEs were 
mild or moderate in severity, and there was no evidence of a 
dose-response for any AE. SAEs were reported in 14 (4.3%) 
patients treated with canakinumab and 6 (5.6%) patients treated 
with colchicine; 2 were considered by the investigator to be pos-
sibly related to study medication: erysipelas of the left leg in 
the canakinumab 25 mg group and cancer of the right kidney 
in the colchicine group. One death occurred in the colchicine 
 Figure  3        Median C reactive protein levels over time. CRP, C reactive 
protein; q4wk, every 4 weeks; ULN, upper limit of the normal range.       
  Table  3      Adverse  events  (safety  set)  
 Variable 
 Canakinumab 
25 mg n=55 
 Canakinumab 
50 mg n=54 
 Canakinumab 
100 mg n=54 
 Canakinumab 
200 mg n=54 
 Canakinumab 
300 mg n=53 
 Canakinumab 
every 4 weeks 
n=53 
 Canakinumab 
Any dose 
n=323 
 Colchicine 
0.5 mg n=108 
Any SAE 2 (3.6) 2 (3.7) 3 (5.6) 3 (5.6) 3 (5.7) 1 (1.9) 14 (4.3) 6 (5.6)
SAE leading to 
discontinuation
1 (1.8) 0 1 (1.9) 2 (3.7) 0 0 4 (1.2) 2 (1.9)
Any serious 
infectious AE
1 (1.8) 0 0 2 (3.7) 0 1 (1.9) 4 (1.2) 0
Any AE 29 (52.7) 30 (55.6) 28 (51.9) 28 (51.9) 29 (54.7) 31 (58.5) 175 (54.2) 58 (53.7)
Any severe AE 4 (7.3) 4 (7.4) 2 (3.7) 3 (5.6) 1 (1.9) 0 14 (4.3) 6 (5.6)
Any infectious AE 11 (20.0) 8 (14.8) 10 (18.5) 11 (20.4) 8 (15.1) 10 (18.9) 58 (18.0) 13 (12.0)
Injection-site reaction 5 (9.1) 4 (7.4) 4 (7.4) 3 (5.6) 2 (3.8) 2 (3.8) 20 (6.2) 4 (3.7)
AE reported in >5% of patients in any group
  Headache 4 (7.3) 3 (5.6) 1 (1.9) 2 (3.7) 6 (11.3) 3 (5.7) 19 (5.9) 6 (5.6)
  Arthralgia 4 (7.3) 5 (9.3) 4 (7.4) 2 (3.7) 3 (5.7) 2 (3.8) 20 (6.2) 3 (2.8)
  Hypertension 6 (10.9) 2 (3.7) 2 (3.7) 5 (9.3) 4 (7.5) 2 (3.8) 21 (6.5) 1 (0.9)
   Upper  respiratory 
tract infection
2 (3.6) 1 (1.9) 2 (3.7) 3 (5.6) 1 (1.9) 3 (5.7) 12 (3.7) 4 (3.7)
  Back pain 3 (5.5) 3 (5.6) 1 (1.9) 3 (5.6) 0 0 10 (3.1) 4 (3.7)
  Nasopharyngitis 5 (9.1) 2 (3.7) 2 (3.7) 0 0 3 (5.7) 12 (3.7) 1 (0.9)
  Diarrhoea 3 (5.5) 1 (1.9) 2 (3.7) 3 (5.6) 1 (1.9) 0 10 (3.1) 2 (1.9)
  Nausea 2 (3.6) 1 (1.9) 3 (5.6) 0 0 1 (1.9) 7 (2.2) 1 (0.9)
   Elevated  alanine 
aminotransferase
3 (5.5) 1 (1.9) 0 1 (1.9) 0 0 5 (1.5) 1 (0.9)
   Elevated  aspartate 
aminotransferase
3 (5.5) 1 (1.9) 0 1 (1.9) 0 0 5 (1.5) 1 (0.9)
  Rash 1 (1.8) 1 (1.9) 0 0 0 3 (5.7) 5 (1.5) 1 (0.9)
 Sinus  congestion 0 0 0 0 3 (5.7) 0 3 (0.9) 1 (0.9)
      AE, adverse event; SAE, serious AE.     
 Figure  2        Time to ﬁ  rst acute gouty arthritis ﬂ  are after randomisation 
(Kaplan–Meier  estimate).    
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  prophylaxis against ﬂ  ares in patients initiating ULT when given 
at doses lower than those used to treat acute gouty arthritis 
ﬂ  ares. 
  Accumulating data thus suggest that canakinumab is an effec-
tive new treatment option for patients with gouty arthritis and 
may be particularly valuable for patients with difﬁ  cult-to-treat 
disease. Such patients frequently have comorbidities and may 
be unable to receive standard anti-inﬂ  ammatory  therapies.    5    
Results of a recent phase II study in patients with contraindica-
tions to non-steroidal anti-inﬂ  ammatory drugs and/or colchicine 
have shown that canakinumab 150 mg provided effective pain 
relief and reduced the risk of new ﬂ  ares.    28    This suggests that 
canakinumab is an effective treatment for acute gouty arthritis 
in patients with limited treatment options due to comorbidities. 
Ongoing phase III studies in this setting should help conﬁ  rm the 
value of canakinumab for the treatment of this growing patient 
population who for whom improved treatment options are 
urgently required. 
  Canakinumab was generally well tolerated. Few patients 
experienced SAEs, severe AEs, or injection-site reactions. No 
organ toxicity and no dose-response for any AE were observed, 
and only one SAE was reported that was considered possibly 
related to canakinumab treatment. The safety proﬁ  le of canaki-
numab reported here is consistent with that previously reported 
for treatment of acute gouty arthritis,    28    and for patients with 
CAPS receiving canakinumab 150 mg at 8-week intervals for up 
to 48 weeks.    32    
  Colchicine doses of 0.5–1.0 mg/day are recommended by The 
European League Against Rheumatism and the British Society 
for Rheumatology for prophylaxis against ﬂ  ares in patients initi-
ating ULT.    12        33    In this study we used a colchicine dose of 0.5 mg/
day. The choice of dose was based on the clinical experience of 
the investigators and results of a study indicating that a dose of 
0.6 mg/day is better tolerated than a higher dose.    18    In this par-
ticular study, the planned dose of colchicine prophylaxis was 0.6 
mg twice daily.    18    However, dosing was reduced to once daily 
in approximately two-thirds of patients and 38% of patients 
experienced diarrhoea. In three other recent studies in patients 
initiating ULT, a colchicine dose of 0.6 mg/day was employed as 
prophylaxis and signiﬁ  cant rates of diarrhoea were not report-
ed.    17        21        22    The rates of ﬂ  ares reported in these studies during 
colchicine prophylaxis (10% to 15% per month) are comparable 
with those reported in our study for the colchicine group. 
  There are a number of limitations to this study. First, colchicine 
0.5 mg was only given for 16 weeks. The risk of ﬂ  ares following 
initiation of ULT is known to extend for up to a year or longer; 
thus a more prolonged period of colchicine prophylaxis may have 
been appropriate. However, key efﬁ  cacy outcomes including 
the primary outcome were assessed at 16 weeks. Second, occur-
rence and duration of ﬂ  ares was dependent on patients’ assess-
ment. This reﬂ  ects the fact that there are currently no validated 
endpoints for the assessment of gouty arthritis ﬂ  ares. Outcome 
Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) 
have suggested possible endpoints for use in studies of gouty 
arthritis but these have yet to be validated.    34    The endpoints 
used in our study overlap with those suggested by OMERACT 
and use of patient self-reporting for ﬂ  ares is unlikely to have had 
an impact on the results. Third, the study population is prob-
ably not representative of all patients who would beneﬁ  t from 
canakinumab. This reﬂ  ects the need to exclude patients with 
possible risks associated with either treatment and the use of 
the exclusion criteria generally used in clinical trials in patients 
with gouty arthritis. Fourth, allopurinol treatment was initiated 
at 300 mg (or 100 mg or 200 mg if creatinine clearance was <90 
infections (3.7%), nasopharyngitis (3.7%) and inﬂ  uenza (1.2%). 
Upper respiratory tract infections (3.7%) and cystitis (1.9%) 
were the only infections occurring in more than 1% of patients 
receiving colchicine. Six serious infections (erysipelas, gangrene, 
sepsis, tonsillitis, ear infection and pneumonia) were reported in 
four patients receiving canakinumab (  table 3  ). Only the case of 
erysipelas was considered to be possibly related to study medi-
cation. No serious infections were reported in patients receiving 
colchicine. Injection-site reactions were reported in 20 (6.2%) 
patients treated with canakinumab and 4 (3.7%) patients in the 
colchicine group. All events were mild except for one moderate 
event in the canakinumab 50 mg group. One patient (in the 50 
mg group) developed low levels of anti-canakinumab antibodies 
at week 24.         
  DISCUSSION 
  This is the largest randomised, double-blind, active-controlled, 
multicentre trial reported in English in the medical literature to 
date assessing prophylaxis against acute gouty arthritis ﬂ  ares 
during the initiation of ULT. We herein report that a single dose 
of canakinumab, 50–300 mg, or 4-weekly doses given over 
4 months (two doses of 50 mg and two of 25 mg) produced a 
62% to 72% reduction in the mean number of ﬂ  ares per patient 
and a 64% to 72% reduction in the risk of experiencing ≥1 ﬂ  are 
at 16 weeks compared with colchicine. In addition, the percent-
age of patients experiencing at least one ﬂ  are at 16 weeks was 
signiﬁ  cantly lower for all canakinumab doses compared with 
colchicine. Target SU levels (<6 mg/dl) were achieved in 39% to 
54% of patients treated with canakinumab and 46% of patients 
treated with colchicine at 16 weeks, consistent with results of 
other recent studies of allopurinol treatment in patients who 
were hyperuricaemic.    17        21        22    All canakinumab doses were well 
tolerated. These results suggest that canakinumab can provide 
effective prophylaxis against gouty arthritis ﬂ  ares and is well 
tolerated in patients initiating ULT. 
  The results of this study validate the concept that IL-1β is a 
key mediator in the generation of acute gouty arthritis ﬂ  ares 
and hence an appropriate therapeutic target for treatment of 
acute gouty arthritis and prevention of ﬂ  ares. This has previ-
ously been demonstrated in a phase II, dose-ranging study of 
canakinumab as treatment for acute ﬂ   ares in patients with 
difﬁ  cult-to-treat gouty arthritis.    28    In this earlier study the high-
est dose of canakinumab tested, 150 mg, demonstrated con-
sistently superior efﬁ  cacy to triamcinolone acetonide 40 mg 
across all efﬁ  cacy measures assessed including pain reduction 
at 72 h post dose, time to a 50% reduction in pain and the risk 
of recurrent ﬂ  ares. Therefore, the canakinumab 150 mg dose 
has been chosen for further assessment as treatment of acute 
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ml/min) instead of slowly up-titrating from a dose of 50–100 
mg, as suggested in treatment recommendations.    12        33    This may 
have increased the risk of ﬂ  ares compared with a dose-titration 
strategy. However, giving allopurinol at a ﬁ  xed dose is a very 
common practice throughout Europe.    12    
  In conclusion, in this double-blind, active-controlled, multi-
centre study assessing prophylaxis against gouty arthritis ﬂ  ares 
during the initiation of ULT, a single canakinumab dose of 
50–300 mg or 4-weekly dosing over 4 months provided effec-
tive prophylaxis against ﬂ   ares, was superior to the standard 
of care (colchicine) and was well tolerated. Further studies of 
canakinumab 150 mg are being conducted to determine the full 
potential of this new drug for the prevention of ﬂ  ares in patients 
with gouty arthritis.     
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